Early clinical trial experience with vaccine therapies in non-small-cell lung cancer.
Cancer immunotherapy has made great progress because of advances in immunology and molecular biology. Increased understanding of mechanisms by which lung cancer cells escape the immune system and recognition of key tumor antigens and immune system components involved in tumor ignorance have led to the development of a variety of lung cancer vaccines. Immunotherapy has advanced from using nonspecific immunomodulatory agents to lung cancer-specific tumor antigens and tumor cell-derived vaccines. While understanding of immune processes and malignancy has improved, there is great opportunity for further research of vaccine therapies in non-small-cell lung cancer. Herein, we review the development and evolution of early lung cancer vaccine trials.
Ho
Cheryl
C
Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada. cho@bccancer.bc.ca
Ochsenbein
Adrian F
AF
Gautschi
Oliver
O
Davies
Angela M
AM
D019496:Cancer Vaccines / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000628:therapy*; D002986:Clinical Trials as Topic; D006801:Humans; D008175:Lung Neoplasms / Q000628:therapy*
D019496:Cancer Vaccines